Suggested remit: To appraise the clinical and cost effectiveness of CTX001 within its marketing authorisation for treating sickle cell disease.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
|
Further information
|
DHSC referral received
|
| Process |
STA Standard
|
| ID number |
4016
|
Provisional Schedule
| Committee meeting: 2 |
08 May 2024 |
| Expected publication |
17 July 2024 |
Project Team
| Project lead |
Celia Mayers |
Email enquiries
| External Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors |
Vertex (Exagamglogene autotemcel) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Anthony Nolan |
| |
Gene People |
| |
Sickle Cell Society |
| Professional groups |
British Society for Haematology |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
UK Forum on Haemoglobin Disorders |
| Comparator companies |
Masters Specialty Pharma (hydroxycarbamide) – confidentiality agreement not signed, not participating |
| |
Medac GmbH (hydroxycarbamide) - confidentiality agreement not signed, not participating |
| |
Neon Laboratories (hydroxycarbamide) - confidentiality agreement not signed, not participating |
| |
Nova Laboratories (hydroxycarbamide) - confidentiality agreement not signed, not participating |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Cell and Gene Therapy Catapult |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
14 March 2024 - 11 April 2024
|
Draft guidance |
|
14 February 2024
|
Committee meeting |
|
12 December 2023
|
We have taken the decision to move the committee discussion for this appraisal to the meeting of the Highly Specialised Technologies Evaluation Committee on 14 February 2024. Please note that this topic will still be considered as a Single Technology Appraisal.
This decision was taken to allow both this appraisal and the appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – the same therapy in a different indication – to be considered by the same committee.
|
|
08 June 2023
|
Invitation to participate |
|
18 January 2023 - 15 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4016 |
|
28 January 2022
|
In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual